CA2809368C - Methods for detecting anti-he4 antibodies and methods of diagnosis and/or prognosis of conditions associated with he4-expressing cells - Google Patents
Methods for detecting anti-he4 antibodies and methods of diagnosis and/or prognosis of conditions associated with he4-expressing cells Download PDFInfo
- Publication number
- CA2809368C CA2809368C CA2809368A CA2809368A CA2809368C CA 2809368 C CA2809368 C CA 2809368C CA 2809368 A CA2809368 A CA 2809368A CA 2809368 A CA2809368 A CA 2809368A CA 2809368 C CA2809368 C CA 2809368C
- Authority
- CA
- Canada
- Prior art keywords
- antibodies
- amount
- serum
- plasma sample
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 65
- 238000003745 diagnosis Methods 0.000 title abstract description 7
- 238000004393 prognosis Methods 0.000 title description 8
- 206010033128 Ovarian cancer Diseases 0.000 claims abstract description 76
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract description 64
- 210000002966 serum Anatomy 0.000 claims description 41
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 36
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 35
- 229920001184 polypeptide Polymers 0.000 claims description 29
- 238000012286 ELISA Assay Methods 0.000 claims description 28
- 238000003556 assay Methods 0.000 claims description 20
- 239000002773 nucleotide Substances 0.000 claims description 19
- 125000003729 nucleotide group Chemical group 0.000 claims description 19
- 230000027455 binding Effects 0.000 claims description 18
- 108091033319 polynucleotide Proteins 0.000 claims description 12
- 102000040430 polynucleotide Human genes 0.000 claims description 12
- 239000002157 polynucleotide Substances 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 8
- 229960002685 biotin Drugs 0.000 claims 4
- 235000020958 biotin Nutrition 0.000 claims 4
- 239000011616 biotin Substances 0.000 claims 4
- 108090001008 Avidin Proteins 0.000 claims 2
- 108010090804 Streptavidin Proteins 0.000 claims 2
- 238000006911 enzymatic reaction Methods 0.000 claims 2
- 101000955067 Homo sapiens WAP four-disulfide core domain protein 2 Proteins 0.000 abstract description 145
- 102100038965 WAP four-disulfide core domain protein 2 Human genes 0.000 abstract description 141
- 206010028980 Neoplasm Diseases 0.000 abstract description 92
- 239000012472 biological sample Substances 0.000 abstract description 55
- 238000011282 treatment Methods 0.000 abstract description 43
- 238000001514 detection method Methods 0.000 abstract description 14
- 210000004881 tumor cell Anatomy 0.000 abstract description 9
- 238000012544 monitoring process Methods 0.000 abstract description 5
- 239000000203 mixture Substances 0.000 abstract description 2
- 201000011510 cancer Diseases 0.000 description 42
- 210000004027 cell Anatomy 0.000 description 35
- 239000012634 fragment Substances 0.000 description 27
- 108090000623 proteins and genes Proteins 0.000 description 26
- 239000000427 antigen Substances 0.000 description 25
- 102000036639 antigens Human genes 0.000 description 24
- 108091007433 antigens Proteins 0.000 description 24
- 150000001413 amino acids Chemical group 0.000 description 23
- 235000018102 proteins Nutrition 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 21
- 201000010099 disease Diseases 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 238000005406 washing Methods 0.000 description 15
- 238000002965 ELISA Methods 0.000 description 13
- 235000001014 amino acid Nutrition 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 238000001356 surgical procedure Methods 0.000 description 12
- 239000002299 complementary DNA Substances 0.000 description 11
- 210000001672 ovary Anatomy 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 238000010790 dilution Methods 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- 210000002381 plasma Anatomy 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 239000003814 drug Substances 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 238000012123 point-of-care testing Methods 0.000 description 8
- 101710132601 Capsid protein Proteins 0.000 description 7
- 101710193132 Pre-hexon-linking protein VIII Proteins 0.000 description 7
- 239000013060 biological fluid Substances 0.000 description 7
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 7
- 210000004379 membrane Anatomy 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 239000007943 implant Substances 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 101710094648 Coat protein Proteins 0.000 description 5
- 101150074155 DHFR gene Proteins 0.000 description 5
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 5
- 101710125418 Major capsid protein Proteins 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 101710141454 Nucleoprotein Proteins 0.000 description 5
- 101710083689 Probable capsid protein Proteins 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 230000000977 initiatory effect Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 210000004197 pelvis Anatomy 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000009257 reactivity Effects 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 102000052147 human WFDC2 Human genes 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 210000003101 oviduct Anatomy 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 3
- 108020005176 AU Rich Elements Proteins 0.000 description 3
- 241000699802 Cricetulus griseus Species 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 206010051676 Metastases to peritoneum Diseases 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 241000607479 Yersinia pestis Species 0.000 description 3
- 230000004520 agglutination Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000003567 ascitic fluid Anatomy 0.000 description 3
- 238000002820 assay format Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229940022399 cancer vaccine Drugs 0.000 description 3
- 238000009566 cancer vaccine Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 201000010063 epididymitis Diseases 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 210000002747 omentum Anatomy 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- 102100020944 Integrin-linked protein kinase Human genes 0.000 description 2
- 102000013519 Lipocalin-2 Human genes 0.000 description 2
- 108010051335 Lipocalin-2 Proteins 0.000 description 2
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 206010027459 Metastases to lymph nodes Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 208000020560 abdominal swelling Diseases 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 102000004419 dihydrofolate reductase Human genes 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001839 endoscopy Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 108010059517 integrin-linked kinase Proteins 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 238000009806 oophorectomy Methods 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 210000004910 pleural fluid Anatomy 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 238000010837 poor prognosis Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 238000003118 sandwich ELISA Methods 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 210000001138 tear Anatomy 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 208000025444 tumor of salivary gland Diseases 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- URLOWBXNQIYFHV-UHFFFAOYSA-N 6-aminohexanoic acid;1-hydroxypyrrolidine-2,5-dione Chemical compound ON1C(=O)CCC1=O.NCCCCCC(O)=O URLOWBXNQIYFHV-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241001156002 Anthonomus pomorum Species 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- BFVQTKQTUCQRPI-YYEZTRBPSA-N LPS with O-antigen Chemical compound O([C@@H]1[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@@H]4[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]5[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O5)O)O4)O)[C@@H](O)[C@@H](CO)O3)NC(C)=O)[C@@H](O)[C@@H](CO[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)NC(C)=O)O2)NC(C)=O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)OC([C@@H]1O)O[C@H]1[C@H](O)[C@@H]([C@@H](O)COC2[C@H]([C@@H](O)[C@H](OP(O)(O)=O)[C@@H]([C@@H](O)CO)O2)O)OC([C@H]1O)O[C@H]1[C@H](OP(O)(=O)OP(O)(=O)OCCN)[C@@H]([C@@H](O)CO)OC([C@H]1O)O[C@H]1[C@H](O[C@]2(O[C@@H]([C@@H](O)[C@H](O[C@]3(O[C@@H]([C@@H](O)[C@H](OP(O)(=O)OCCN)C3)[C@@H](O)CO)C(O)=O)C2)[C@@H](O)CO)C(O)=O)C[C@](O[C@@H]1[C@@H](O)CO)(OC[C@H]1O[C@@H](OC[C@@H]2[C@H]([C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O2)O)[C@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@H]([C@@H]1OP(O)(O)=O)OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O BFVQTKQTUCQRPI-YYEZTRBPSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 102000004264 Osteopontin Human genes 0.000 description 1
- 108010081689 Osteopontin Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 208000000450 Pelvic Pain Diseases 0.000 description 1
- 102100029500 Prostasin Human genes 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108010010517 TADG-12 serine protease Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 241000656145 Thyrsites atun Species 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 1
- 102000050760 Vitamin D-binding protein Human genes 0.000 description 1
- 101710179590 Vitamin D-binding protein Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 210000000448 cultured tumor cell Anatomy 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 238000011334 debulking surgery Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 125000003712 glycosamine group Chemical group 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003317 immunochromatography Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 101710155777 mRNA export factor ICP27 homolog Proteins 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000030427 mucinous ovarian cancer Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108010031970 prostasin Proteins 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 208000017443 reproductive system disease Diseases 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000013391 scatchard analysis Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000011539 total abdominal hysterectomy Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000009808 unilateral salpingo-oophorectomy Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37738710P | 2010-08-26 | 2010-08-26 | |
| US61/377,387 | 2010-08-26 | ||
| PCT/US2011/049274 WO2012027631A2 (en) | 2010-08-26 | 2011-08-26 | Methods for detecting anti-he4 antibodies and methods of diagnosis and/or prognosis of conditions associated with he4-expressing cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2809368A1 CA2809368A1 (en) | 2012-03-01 |
| CA2809368C true CA2809368C (en) | 2021-08-24 |
Family
ID=45724080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2809368A Active CA2809368C (en) | 2010-08-26 | 2011-08-26 | Methods for detecting anti-he4 antibodies and methods of diagnosis and/or prognosis of conditions associated with he4-expressing cells |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20130224772A1 (enExample) |
| EP (1) | EP2609429B1 (enExample) |
| JP (1) | JP6097688B2 (enExample) |
| CN (1) | CN103180732B (enExample) |
| AU (1) | AU2011293217A1 (enExample) |
| BR (1) | BR112013004458A2 (enExample) |
| CA (1) | CA2809368C (enExample) |
| MX (1) | MX2013002268A (enExample) |
| RU (1) | RU2600891C2 (enExample) |
| WO (1) | WO2012027631A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7270960B2 (en) * | 2001-08-29 | 2007-09-18 | Pacific Northwest Research Institute | Diagnosis of ovarian carcinomas |
| CA2827618C (en) * | 2011-02-17 | 2019-08-06 | Fujirebio Diagnostics, Inc. | Compositions and methods of use for the determination of he4a |
| CN103424551B (zh) * | 2013-08-06 | 2015-08-26 | 江苏福隆生物技术有限公司 | 人附睾上皮分泌蛋白4定量测定试剂盒及其检测方法 |
| US10267802B2 (en) * | 2015-09-23 | 2019-04-23 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of prognosis and diagnosis of ovarian cancer |
| KR102599695B1 (ko) * | 2015-12-17 | 2023-11-07 | 에프. 호프만-라 로슈 아게 | 마커 사람 부고환 단백질 4 (he4) 기반의 폐 선암 재발의 발견 방법 및 관련 용도 |
| CN109280084B (zh) * | 2018-03-09 | 2022-04-29 | 河南大学 | 一种胶体硒标记的抗he4抗体、试剂盒及其制备方法 |
| CN109480771B (zh) * | 2018-10-17 | 2021-09-07 | 江西惠肽生物科技有限公司 | 一种卵巢肿块良恶的确定方法及确定装置 |
| CN110895279B (zh) * | 2019-11-27 | 2023-02-28 | 普健生物（武汉）科技有限公司 | 一种检测人附睾分泌蛋白4的化学发光试剂盒 |
| WO2022204017A1 (en) * | 2021-03-22 | 2022-09-29 | Curative Inc. | Immunization assessments using saliva or nasal specimen |
| CN113045663B (zh) * | 2021-04-18 | 2022-04-01 | 深圳市国创纳米抗体技术有限公司 | 一种抗he4的纳米抗体1a8及其应用 |
| CN117487018B (zh) * | 2023-09-27 | 2024-05-17 | 武汉爱博泰克生物科技有限公司 | 抗人附睾分泌蛋白4的兔单克隆抗体及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5017342A (en) * | 1988-06-01 | 1991-05-21 | Ortho Diagnostic Systems Inc. | Device for immunoassay determinations |
| AU2002241720A1 (en) * | 2000-11-08 | 2002-06-18 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer |
| US7270960B2 (en) * | 2001-08-29 | 2007-09-18 | Pacific Northwest Research Institute | Diagnosis of ovarian carcinomas |
| US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| EP1924710B1 (en) * | 2005-09-15 | 2011-03-30 | Val-Chum, S.E.C. | Methods of diagnosing ovarian cancer |
| EP2982761B1 (en) * | 2006-01-04 | 2017-10-04 | Fujirebio America, Inc. | Use of he4 and other biochemical markers for assessment of endometrial and uterine cancers |
| AU2007297310B2 (en) * | 2006-09-13 | 2013-11-07 | Oncimmune Limited | Improved immunoassay methods |
| KR20100015438A (ko) * | 2007-03-09 | 2010-02-12 | 트리패스 이미징, 인코포레이티드 | Ｈｅ4 모노클로날 항체 및 이의 사용 방법 |
| EP2126577B1 (en) * | 2007-03-29 | 2013-03-13 | Fujirebio Diagnostics, Inc. | Use of he4 for assessment of breast cancers |
| WO2010061393A1 (en) * | 2008-11-30 | 2010-06-03 | Compugen Ltd. | He4 variant nucleotide and amino acid sequences, and methods of use thereof |
| CN101525614A (zh) * | 2009-04-13 | 2009-09-09 | 大连美亿德生物科技有限公司 | 人卵巢癌肿瘤标志物he4酶联免疫诊断试剂盒 |
-
2011
- 2011-08-26 CA CA2809368A patent/CA2809368C/en active Active
- 2011-08-26 CN CN201180051336.5A patent/CN103180732B/zh active Active
- 2011-08-26 US US13/818,466 patent/US20130224772A1/en not_active Abandoned
- 2011-08-26 AU AU2011293217A patent/AU2011293217A1/en not_active Abandoned
- 2011-08-26 WO PCT/US2011/049274 patent/WO2012027631A2/en not_active Ceased
- 2011-08-26 BR BR112013004458A patent/BR112013004458A2/pt not_active IP Right Cessation
- 2011-08-26 JP JP2013526167A patent/JP6097688B2/ja active Active
- 2011-08-26 RU RU2013113314/15A patent/RU2600891C2/ru active
- 2011-08-26 MX MX2013002268A patent/MX2013002268A/es unknown
- 2011-08-26 EP EP11820697.8A patent/EP2609429B1/en active Active
-
2018
- 2018-01-25 US US15/879,963 patent/US20180217158A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011293217A1 (en) | 2013-04-11 |
| JP6097688B2 (ja) | 2017-03-15 |
| JP2013536442A (ja) | 2013-09-19 |
| EP2609429A2 (en) | 2013-07-03 |
| CN103180732A (zh) | 2013-06-26 |
| CN103180732B (zh) | 2017-09-08 |
| US20180217158A1 (en) | 2018-08-02 |
| EP2609429B1 (en) | 2017-09-20 |
| CA2809368A1 (en) | 2012-03-01 |
| WO2012027631A3 (en) | 2012-07-19 |
| RU2600891C2 (ru) | 2016-10-27 |
| MX2013002268A (es) | 2014-02-03 |
| BR112013004458A2 (pt) | 2016-06-07 |
| WO2012027631A2 (en) | 2012-03-01 |
| RU2013113314A (ru) | 2014-10-10 |
| EP2609429A4 (en) | 2014-03-19 |
| US20130224772A1 (en) | 2013-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2809368C (en) | Methods for detecting anti-he4 antibodies and methods of diagnosis and/or prognosis of conditions associated with he4-expressing cells | |
| US7846692B2 (en) | HE4 monoclonal antibodies and methods for their use | |
| EP3026119B1 (en) | Use of he4 and other biochemical markers for assessment of ovarian cancers | |
| US20100227335A1 (en) | Matrix metalloproteinase-7 (mmp-7) monoclonal antibodies and methods for their use in the detection of ovarian cancer | |
| US8252904B2 (en) | Glycodelin monoclonal antibodies and methods for their use in the detection of ovarian cancer | |
| CN104136630A (zh) | 诊断和预示乳腺癌的标志物 | |
| US20090042224A1 (en) | Methods for diagnosis and/or prognosis of ovarian cancer | |
| JP6729917B2 (ja) | ＥｐｈＡ２ Ｎ末端フラグメント抗体 | |
| HK1187100B (en) | Methods for detecting anti-he4 antibodies and methods of diagnosis and/or prognosis of conditions associated with he4-expressing cells | |
| HK1187100A (en) | Methods for detecting anti-he4 antibodies and methods of diagnosis and/or prognosis of conditions associated with he4-expressing cells | |
| CN115873117B (zh) | 一种pd-l1单克隆抗体或其抗原结合片段及检测试剂盒 | |
| HK1225411B (en) | Use of he4 and other biochemical markers for assessment of ovarian cancers | |
| HK1225411A1 (en) | Use of he4 and other biochemical markers for assessment of ovarian cancers | |
| HK1225411A (en) | Use of he4 and other biochemical markers for assessment of ovarian cancers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20160819 |